A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma

Multiple myeloma (MM) remains incurable despite advances in treatment options. Although tumor subtypes and specific DNA abnormalities are linked to worse prognosis, the impact of immune dysfunction on disease emergence and/or treatment sensitivity remains unclear. We developed an Immune Atlas of MM by generating profiles of 1,397,272 single cells from the bone marrow (BM) of 337 newly diagnosed participants and characterized immune and hematopoietic cell populations. Cytogenetic risk-based analysis revealed heterogeneous associations with T cells of BM, with 17p13 deletion showing distinct enrichment of a type 1 interferon signature. The disease progression-based analysis revealed the presence of a proinflammatory immune senescence-associated secretory phenotype in rapidly progressing participants. Furthermore, signaling analyses suggested active intercellular communication involving a proliferation-inducing ligand and B cell maturation antigen, potentially promoting tumor growth and survival. Lastly, using independent discovery and validation cohorts, we demonstrated that integrating immune cell signatures with known tumor cytogenetics and individual characteristics significantly improves stratification for the prediction of survival.

Authors

Institutions

Publication Details

Journal
Nature Cancer
Published
2026-01-09
DOI
https://doi.org/10.1038/s43018-025-01072-4
Citations
1
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
35.41
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma

Michael Slade, Mojtaba Bakhtiari, Michael Strausbauch, Dimitra Karagkouni et al.
1 citations
Nature Cancer
Multiple Myeloma Research and Treatments
35.41
article

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma

Michael Slade, Mojtaba Bakhtiari, Michael Strausbauch, Dimitra Karagkouni, R Chen, B. Lee, Omar Ibrahim, T. Kourelis, Chaitanya R. Acharya, Shivani Nanda, Julie M. Fortier, Denis Ohlstrom, H. J. Cho, T. Fehniger, Yuling Ma, Eva M. Lepisto, Kazuhito Sato, M. Fiala, Jacalyn Rosenblatt, Rania Alaaeldin, Jessica Schulman, Jennifer A. Foltz, Sarthak Satpathy, J. DiPersio, Avigan De, Travis Dawson, Giulia Cheloni, Katherine Ferguson, Andrew Houston, Alessandro Laganà, Jayasinghe Rg, Isabella Saldarriaga, Nick Pabustan, Krista Angeliadis, Vernadette A Simon, Jarod Morgenroth-Rebin, Emir Radkevich, William C. Pilcher, Eric Anderson, Sagar Lonial, Shaji Kumar, Laura Walker, Ravi Vij, Roderick Lin, Igor Figueiredo, Song Cao, Nikolaos Kalavros, Yizhe Song, Junia Vieira Dos Santos, Geoffrey Kelly, Darwin D’Souza, Chiang I-ling, Madhav V. Dhodapkar, Manoj Bhasin, Kai Nie, April Cook, Li Ding, Sacha Gnjatic, I-ling Chiang, Beena E. Thomas, Edgar Gonzalez-Kozlova, Jennifer Rogers, Zhihong Chen, Ioannis S. Vlachos, Matthew A. Wyczalkowski, Stephen T. Oh, Nicolas F. Fernandez, John Leech, Ying Li, Lijun Yao, George Mulligan, Mark Hamilton, Surendra Dasari, Michael P. Rettig, Swati S. Bhasin, Marina E. Michaud, Seunghee Kim-Schulze, Julia T. Wang
article en
1 citations

Abstract

Multiple myeloma (MM) remains incurable despite advances in treatment options. Although tumor subtypes and specific DNA abnormalities are linked to worse prognosis, the impact of immune dysfunction on disease emergence and/or treatment sensitivity remains unclear. We developed an Immune Atlas of MM by generating profiles of 1,397,272 single cells from the bone marrow (BM) of 337 newly diagnosed participants and characterized immune and hematopoietic cell populations. Cytogenetic risk-based analysis revealed heterogeneous associations with T cells of BM, with 17p13 deletion showing distinct enrichment of a type 1 interferon signature. The disease progression-based analysis revealed the presence of a proinflammatory immune senescence-associated secretory phenotype in rapidly progressing participants. Furthermore, signaling analyses suggested active intercellular communication involving a proliferation-inducing ligand and B cell maturation antigen, potentially promoting tumor growth and survival. Lastly, using independent discovery and validation cohorts, we demonstrated that integrating immune cell signatures with known tumor cytogenetics and individual characteristics significantly improves stratification for the prediction of survival.

Nature CancerVol. 7(1)
Broad Institute (US), Georgia Institute of Technology (US), Beth Israel Deaconess Medical Center (US), Emory Healthcare (US), Harvard University (US), Emory University (US), Emory and Henry College (US), Washington University in St. Louis (US), Multiple Myeloma Research Foundation (US), Aflac (United States) (US), Mayo Clinic in Arizona (US), Tisch Hospital (US), Children's Healthcare of Atlanta (US), Winship Cancer Institute, Icahn School of Medicine at Mount Sinai (US)
Good health and well-being
Openalex Percentile: Top 2%
Multiple Myeloma Research and Treatments
35.41
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.